← Leaderboards
George Louis Drusano
University Of Florida
$18,475,919
Attributed
$28,693,079
Total exposure
14
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.3M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$51,775,174 · 17
By mechanism
P01$28,980,991 · 9
R01$21,704,151 · 6
R56$1,075,032 · 1
R13$15,000 · 1
Top collaborators
- Arnold Louie22 shared
- Ashley Brown5 shared
- Jurgen Bernd Bulitta1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Arnold Louie$12,883,478
- L T Spencer$1,014,888
- Michael N. Neely$9,304,264
- Yinzhi Lang$1,261,878
- Ashley Brown$2,797,681
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionPharmaceutical PreparationsFiberResistanceRegimenMathematical ModelCombined Modality TherapyDoseDrug CombinationsSiteOrganismDrug KineticsPathogenScheduleIn VitroEvaluationMouse ModelPreventBiological ModelsInnovationDesignResistance MechanismBaseDosage
Grant awards (58)
Project 2 Hollow Fiber Project$295,557
P01 · FY2025 · AI · contact PI
Core 1 Administrative Core$290,101
P01 · FY2025 · AI · contact PI
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is$2,308,174
P01 · FY2024 · AI · contact PI
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression$1,403,884
R01 · FY2024 · AI · contact PI
Project 2 Hollow Fiber Project$275,732
P01 · FY2024 · AI · contact PI
Core 1 Administrative Core$268,284
P01 · FY2024 · AI · contact PI
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression$1,314,301
R01 · FY2023 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,619,058
P01 · FY2020 · AI · contact PI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$687,939
R01 · FY2020 · AI · contact PI
Hollow Fiber Infection Model to Delineate Combination Drug Interaction for Different MTB Metabolic Populations and using Different Pharmacokinetic Profiles$462,859
P01 · FY2020 · AI · contact PI
Administrative Core$116,797
P01 · FY2020 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,710,457
P01 · FY2019 · AI · contact PI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$932,445
R01 · FY2019 · AI · contact PI
Hollow Fiber Infection Model to Delineate Combination Drug Interaction for Different MTB Metabolic Populations and using Different Pharmacokinetic Profiles$622,032
P01 · FY2019 · AI · contact PI
Administrative Core$126,755
P01 · FY2019 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,332,983
P01 · FY2018 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,096,497
R01 · FY2018 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$1,007,027
R01 · FY2018 · AI · contact PI
Hollow Fiber Infection Model to Delineate Combination Drug Interaction for Different MTB Metabolic Populations and using Different Pharmacokinetic Profiles$684,266
P01 · FY2018 · AI · contact PI
Administrative Core$130,541
P01 · FY2018 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$1,988,816
P01 · FY2017 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,103,751
R01 · FY2017 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$729,901
R01 · FY2017 · AI · contact PI
Hollow Fiber Infection Model to Delineate Combination Drug Interaction for Different MTB Metabolic Populations and using Different Pharmacokinetic Profiles$681,864
P01 · FY2017 · AI · contact PI
Administrative Core$133,784
P01 · FY2017 · AI · contact PI
Optimizing Combination Therapy to Accelerate Clinical Cure of Tuberculosis$2,336,318
P01 · FY2016 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,120,190
R01 · FY2016 · AI
Rapid Identification of Optimal Combination Regimens for Pseudomonas aeruginosa$751,274
R01 · FY2016 · AI · contact PI
Hollow Fiber Infection Model to Delineate Combination Drug Interaction for Different MTB Metabolic Populations and using Different Pharmacokinetic Profiles$489,361
P01 · FY2016 · AI · contact PI
Administrative Core$127,547
P01 · FY2016 · AI · contact PI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,127,672
R01 · FY2015 · AI
Optimizing combination therapy for Hepatitis C virus with pharmacodynamic models$1,147,252
R01 · FY2014 · AI
Combination Therapy Modeling for M tuberculosis Resistance Suppression and Kill$1,075,032
R56 · FY2014 · AI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$724,489
R01 · FY2014 · AI · contact PI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$657,363
R01 · FY2013 · AI · contact PI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$687,841
R01 · FY2012 · AI · contact PI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$1,044,441
R01 · FY2011 · AI · contact PI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$626,816
R01 · FY2011 · AI · contact PI
Resistance Suppression for Influenza Virus With Combination Chemotherapy$558,357
R01 · FY2011 · AI · contact PI
Optimization of Neoglycoside Antibiotics for Nosocomial Pathogens and Select Agen$874,998
R01 · FY2010 · AI · contact PI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$750,762
R01 · FY2010 · AI · contact PI
Resistance Suppression for Influenza Virus With Combination Chemotherapy$571,330
R01 · FY2010 · AI · contact PI
2010 New Antimicrobial Drug Discovery and Development Gordon Research Conference$15,000
R13 · FY2010 · AI · contact PI
Choosing Drug Doses for Biodefense Pathogens$1,860,566
P01 · FY2009 · AI · contact PI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$782,530
R01 · FY2009 · AI · contact PI
Resistance Suppression for Influenza Virus With Combination Chemotherapy$651,410
R01 · FY2009 · AI · contact PI
CORE--Computational Modeling$178,601
P01 · FY2009 · AI · contact PI
Choosing Drug Doses for Biodefense Pathogens$1,887,352
P01 · FY2008 · AI · contact PI
Resistance Suppression for P. Aeruginosa using Novel Combination Therapy Modeling$787,916
R01 · FY2008 · AI · contact PI
Resistance Suppression for Influenza Virus With Combination Chemotherapy$563,765
R01 · FY2008 · AI · contact PI
CORE--Computational Modeling$181,139
P01 · FY2008 · AI · contact PI
Choosing Drug Doses for Biodefense Pathogens$1,788,209
P01 · FY2007 · AI · contact PI
CORE--Computational Modeling$246,172
P01 · FY2007 · AI · contact PI
Choosing Drug Doses for Biodefence Pathogens$1,787,477
P01 · FY2006 · AI · contact PI
CORE--Computational Modeling$212,375
P01 · FY2006 · AI · contact PI
Choosing Drug Doses for Biodefense Pathogens$1,462,685
P01 · FY2005 · AI
CORE--Computational Modeling$189,274
P01 · FY2005 · AI
Administration Core$185,855
P01 · FY2005 · AI